616224-38-5

Basic information

• Product Name: Methyl 4-aMino-3-(MethylaMino)benzoate
• Synonyms: Methyl 4-aMino-3-(MethylaMino)benzoate
• CAS NO: 616224-38-5
• Molecular Formula: C₉H₁₂N₂O₂
• Molecular Weight: 180.20378
• Mol File: 616224-38-5.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 369.9±32.0 °C(Predicted)
• Appearance: /
• Density: 1.208±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.42±0.10(Predicted)
• CAS DataBase Reference: Methyl 4-aMino-3-(MethylaMino)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-aMino-3-(MethylaMino)benzoate(616224-38-5)
• EPA Substance Registry System: Methyl 4-aMino-3-(MethylaMino)benzoate(616224-38-5)

Safety Data

• Hazardous Substances Data: 616224-38-5(Hazardous Substances Data)

Usage

Description

Methyl 4-amino-3-(methylamino)benzoate, a chemical compound with the molecular formula C9H12N2O2, is an organic compound that serves as an intermediate in the synthesis of pharmaceuticals and organic compounds. Its unique structure and pharmacological properties make it a promising candidate for the development of new drugs and medicines.

Uses

Used in Pharmaceutical Industry:
Methyl 4-amino-3-(methylamino)benzoate is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and medicines. Its unique chemical structure allows for the creation of compounds with potential therapeutic applications.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, Methyl 4-amino-3-(methylamino)benzoate is utilized as an intermediate for synthesizing a range of organic compounds. Its presence in these reactions can lead to the formation of new molecules with diverse applications in various industries.
While the provided materials do not specify particular applications or industries for Methyl 4-amino-3-(methylamino)benzoate, its role as an intermediate in pharmaceutical and organic compound synthesis highlights its versatility and potential for future development in these areas.

Upstream product

• 616224-36-3 4-tert-butoxycarbonylamino-3-methylaminobenzoic acid methyl ester 
• 251643-13-7 methyl 3-(methylamino)-4-nitrobenzoate 
• 124-38-9 carbon dioxide 
• 36692-49-6 Methyl 3,4-diaminobenzoate 
• 185629-31-6 methyl 3-fluoro-4-nitrobenzoate 

Downstream Products

• 131020-50-3 methyl 1-methyl-1H-benzo[d]imidazole-6-carboxylate 
• 863564-77-6 3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylic acid 
• 1038387-93-7 methyl 1,2-dimethyl-1H-benzimidazole-6-carboxylate 
• 53484-18-7 1-methyl-6-benzimidazole carboxylic acid 

Relevant articles and documents

Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

Secondary mutations of FLT3 have become the main mechanism of FLT3 inhibitor resistance that presents a significant clinical challenge. Herein, a series of pyrazole-3-amine derivatives were synthesized and optimized to overcome the common secondary resistance mutations of FLT3. The structure-activity relationship and molecular dynamics simulation studies illustrated that the ribose region of FLT3 could be occupied to help address the obstacle of secondary mutations. Among those derivatives, compound 67 exhibited potent and selective inhibitory activities against FLT3-ITD-positive acute myeloid leukemia (AML) cells and possessed equivalent potency against transformed BaF3 cells with a variety of secondary mutations. Besides, cellular mechanism assays demonstrated that 67 strongly inhibited phosphorylation of FLT3 and its downstream signaling factors, as well as induced cell cycle arrest and apoptosis in MV4-11 cells. In the MV4-11 xenograft models, 67 exhibited potent antitumor potency without obvious toxicity. Taken together, these results demonstrated that 67 might be a drug candidate for the treatment of FLT3-ITD-positive AML.

EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION

Provided are compounds of Formula (I), pharmaceutical compositions comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

Novel compounds that are inhibitors of YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma

These compounds are useful as inhibitors of the YAP/TAZ-TEAD interaction.